AP
IMGN

Arlington Partners’s Immunogen Inc IMGN Stock Holding History

Arlington Partners’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-115
Closed -$1K – 416
2020
Q4 		$1K Buy
+115
New +$671 ﹤0.01% 224

Other funds holding IMGN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Arlington Partners's IMGN Position: Q1 2021 in Review

Arlington Partners sold out of Immunogen Inc (IMGN) in Q1 2021, closing a stake of 115 shares — an estimated $1K sold.

Arlington Partners first reported a position in IMGN in Q4 2020 and held it in 1 quarter. The position peaked at $1K in Q4 2020. 217 funds tracked by Wall St. Rank hold IMGN as of Q1 2021.

  • Arlington Partners reported no remaining Immunogen Inc position as of Q1 2021 after selling out during the quarter.
  • Arlington Partners sold 115 Immunogen Inc shares in Q1 2021, an estimated $1K.
  • Arlington Partners first reported a position in Immunogen Inc in Q4 2020 and held it in 1 quarter.
  • Arlington Partners's Immunogen Inc position peaked at $1K in Q4 2020.
  • 217 funds tracked by Wall St. Rank held Immunogen Inc as of Q1 2021.

Based on Arlington Partners's 13F filing for Q1 2021, filed 19 Apr 2021.